342 related articles for article (PubMed ID: 25856810)
1. Brexpiprazole: another multipurpose antipsychotic drug?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2015 Apr; 53(4):23-5. PubMed ID: 25856810
[TBL] [Abstract][Full Text] [Related]
2. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
3. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
[TBL] [Abstract][Full Text] [Related]
4. Brexpiprazole for the treatment of schizophrenia.
Hsu WY; Lane HY; Lin CH
Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
[TBL] [Abstract][Full Text] [Related]
5. Brexpiprazole.
Markovic M; Gallipani A; Patel KH; Maroney M
Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
[TBL] [Abstract][Full Text] [Related]
6. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
[No Abstract] [Full Text] [Related]
7. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
Stummer L; Markovic M; Maroney M
Neurodegener Dis Manag; 2020 Aug; 10(4):205-217. PubMed ID: 32618483
[TBL] [Abstract][Full Text] [Related]
8. Brexpiprazole: First Global Approval.
Greig SL
Drugs; 2015 Sep; 75(14):1687-97. PubMed ID: 26310190
[TBL] [Abstract][Full Text] [Related]
9. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Citrome L; Stensbøl TB; Maeda K
Expert Rev Neurother; 2015 Oct; 15(10):1219-29. PubMed ID: 26402059
[TBL] [Abstract][Full Text] [Related]
10. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
Citrome L
Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
[TBL] [Abstract][Full Text] [Related]
11. Brexpiprazole for the treatment of schizophrenia.
Yee A
Expert Rev Neurother; 2016; 16(2):109-22. PubMed ID: 26650624
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Antoun Reyad A; Girgis E; Mishriky R
Int Clin Psychopharmacol; 2020 May; 35(3):119-128. PubMed ID: 32141908
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of brexpiprazole: comparison with aripiprazole.
Stahl SM
CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
[TBL] [Abstract][Full Text] [Related]
14. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Citrome L; Ota A; Nagamizu K; Perry P; Weiller E; Baker RA
Int Clin Psychopharmacol; 2016 Jul; 31(4):192-201. PubMed ID: 26963842
[TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
Edinoff AN; Wu NW; Maxey BS; Ren AL; Leethy KN; Girma B; Odisho A; Kaye JS; Kaye AJ; Kaye AM; Kaye AD; Mychaskiw G; Viswanath O; Urits I
Psychopharmacol Bull; 2021 Mar; 51(2):69-95. PubMed ID: 34092824
[TBL] [Abstract][Full Text] [Related]
16. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
McEvoy J; Citrome L
Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
Nelson JC; Weiller E; Zhang P; Weiss C; Hobart M
J Affect Disord; 2018 Feb; 227():103-108. PubMed ID: 29055257
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression.
Bruijnzeel D; Tandon R
Drug Des Devel Ther; 2016; 10():1641-7. PubMed ID: 27274197
[TBL] [Abstract][Full Text] [Related]
19. Brexpiprazole for treatment-resistant major depressive disorder.
Fornaro M; Fusco A; Anastasia A; Cattaneo CI; De Berardis D
Expert Opin Pharmacother; 2019 Nov; 20(16):1925-1933. PubMed ID: 31431092
[No Abstract] [Full Text] [Related]
20. The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
Aladeen T; Westphal E; Lee Y; Rong C; Rainka M; Capote H; McIntyre RS
Perspect Psychiatr Care; 2018 Oct; 54(4):507-513. PubMed ID: 29427512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
